Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer

touchEXPERT OPINIONS for touchONCOLOGY A gynaecological oncologist considers the expanding role of molecular classification in endometrial cancer and provides an update on the use of immune checkpoint inhibitors to treat patients with advanced or recurrent disease, including key guideline recommendations, supporting data and considerations for clinical practice. The expert Prof. David Cibula, General University Hospital and Charles University, Prague, Czech Republic This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Merck & Co, Inc.  This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/immunotherapy-in-endometrial-cancer/